Stockscreener 앱 받기
30.07
7.53%
-2.45
전일 마감가:
$32.52
열려 있는:
$32.56
하루 거래량:
351.76K
Relative Volume:
0.86
시가총액:
$1.40B
수익:
순이익/손실:
주가수익비율:
-36.96
EPS:
-0.8135
순현금흐름:
1주 성능:
-4.90%
1개월 성능:
-26.60%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$29.87
$32.56
1주일 범위
$29.01
$33.50
52주 변동 폭
$23.00
$55.42
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
명칭
Hemab Therapeutics Holdings Inc
전화
45 2138 7627
주소
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
30.07 | 1.40B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Hemab Therapeutics Holdings Inc Stock (COAG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-15 | 개시 | JP Morgan | Overweight |
| 2026-10-12 | 개시 | Rodman & Renshaw | Buy |
| 2026-06-17 | 개시 | H.C. Wainwright | Buy |
| 2026-05-26 | 개시 | Evercore ISI | Outperform |
| 2026-05-26 | 개시 | Goldman | Buy |
| 2026-05-26 | 개시 | Jefferies | Buy |
| 2026-05-26 | 개시 | Wedbush | Outperform |
모두보기
Hemab Therapeutics Holdings Inc 주식(COAG)의 최신 뉴스
Hemab Therapeutics (NASDAQ:COAG) Stock Price Up 8.4%Here's What Happened - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 7.5%What's Next? - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount? - Yahoo Finance
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount? - Yahoo Finance UK
76,900 Shares in Hemab Therapeutics Holdings, Inc. $COAG Bought by State Street Corp - MarketBeat
Form 4 Hemab Therapeutics Holdings For: 25 September - Investing.com India
Form 4 Hemab Therapeutics Holdings For: 25 September By Investing.com - Investing.com Canada
Form 4 Hemab Therapeutics Holdings For: 25 September By Investing.com - Investing.com UK
Director Walbert Keli's option carries a $35.72 exercise price at Hemab Therapeutics (COAG). - stocktitan.net
Hemab Therapeutics Holdings, Inc. (COAG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Can Hemab Therapeutics Holdings (COAG) Justify Its Valuation After Russell Index Inclusion? - Simply Wall Street
Hemab Therapeutics (NASDAQ:COAG) Shares Down 5.7%What's Next? - MarketBeat
Hemab Therapeutics Holdings (Nasdaq:COAG)Stock Analysis - simplywall.st
Hemab Therapeutics Holdings, Inc.(NasdaqGS:COAG) added to Russell 3000 Value Benchmark - marketscreener.com
Heavy menstrual bleeding affects 1 in 3 women. Hemab begins testing a new treatment. - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Shares Up 7.6%Time to Buy? - MarketBeat
Opaleye Management Inc. Makes New Investment in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Trading Down 6.8%What's Next? - MarketBeat
Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Braidwell LP Purchases New Shares in Hemab Therapeutics Holdings, Inc. $COAG - MarketBeat
Biopharma IPO class of 2026: share price up 66% on average - BioWorld News
Hemab Therapeutics (NASDAQ:COAG) Trading Down 8.4%Here's What Happened - MarketBeat
AppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors - Yahoo Finance
Capital International Investors Establishes New Position in Hema - GuruFocus
Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics - Stock Titan
Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake - Stock Titan
20 Years of Prix Galien USA Brings a New Nominee Class—Who Wins? - Stock Titan
HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics - MarketBeat
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership - Stock Titan
Hemab Therapeutics stock price target raised to $60 by H.C. Wainwright - Investing.com Canada
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FMR LLC Acquires Stake in Hemab Therapeutics Holdings Inc (COAG) - GuruFocus
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Hemab Therapeutics Reports Q2 2026 Financials and Pipeline Progress in Latest 10-Q Filing - Kalkine Media
Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com South Africa
Hemab Therapeutics Gains FDA Backing to Advance Sutacimig Into Phase 3 Trial for Glanzmann Thrombasthenia - Minichart
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com Nigeria
Hemab Therapeutics' Q2 Net Loss Narrows - marketscreener.com
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com Canada
Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Hemab Therapeutics Holdings Inc (COAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hemab Therapeutics Holdings Inc 주식 (COAG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Jun 15 '26 |
Buy |
24.89 |
6,146 |
152,974 |
6,383,114 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 20 '26 |
Buy |
24.94 |
996 |
24,840 |
6,376,968 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 19 '26 |
Buy |
24.97 |
3,802 |
94,936 |
6,375,972 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 12 '26 |
Buy |
24.90 |
6,387 |
159,036 |
6,372,170 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 11 '26 |
Buy |
24.81 |
39,869 |
989,226 |
6,365,783 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 08 '26 |
Buy |
24.98 |
1,483 |
37,045 |
6,325,914 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 07 '26 |
Buy |
24.46 |
9,906 |
242,323 |
6,324,431 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 06 '26 |
Buy |
24.60 |
68,018 |
1,673,399 |
6,314,525 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 05 '26 |
Buy |
24.63 |
97,411 |
2,399,546 |
6,246,507 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 04 '26 |
Buy |
18.00 |
2,675,000 |
48,150,000 |
6,149,096 |
7.09%
4.63%
자본화:
|
볼륨(24시간):